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Background:  A tetravalent  dengue  vaccine  was  shown  to  be efﬁcacious  against  symptomatic  dengue  in
two  phase  III  efﬁcacy  studies  performed  in  ﬁve  Asian  and ﬁve  Latin  American  countries.  The  objective
here  was to estimate  key  parameters  of a  dengue  transmission  model  using  the  data  collected  during
these  studies.
Methods:  Parameter  estimation  was  based  on a Sequential  Monte  Carlo  approach  and  used  a  cohort
version  of the transmission  model.  Serotype-speciﬁc  basic  reproduction  numbers  were  derived  for  each
country.  Parameters  related  to serotype  interactions  included  duration  of cross-protection  and  level of
cross-enhancement  characterized  by differences  in symptomaticity  for  primary,  secondary  and  post-
secondary  infections.  We  tested  several  vaccine  efﬁcacy  proﬁles  and  simulated  the  evolution  of  vaccine
efﬁcacy  over  time  for  the scenarios  providing  the best  ﬁt to the  data.
Results:  Two  reference  scenarios  were  identiﬁed.  The  ﬁrst  included  temporary  cross-protection  and  the
second  combined  cross-protection  and  cross-enhancement  upon  wild-type  infection  and  following  vac-
cination.  Both  scenarios  were  associated  with  differences  in efﬁcacy  by  serotype,  higher  efﬁcacy  for
pre-exposed  subjects  and  against  severe  dengue,  increase  in  efﬁcacy  with  doses  for  naïve subjects  and
by a  more  important  waning  of  vaccine  protection  for subjects  when  naïve  than  when  pre-exposed.  Over
Vaccine  (2016) 6417–642534
November 20152120 years,  the  median  reduction  of  dengue  risk  induced  by  the  direct  protection  conferred  by  the vaccine
ranged  from  24%  to 47%  according  to country  for the ﬁrst  scenario  and  from  34%  to  54% for  the  second.
Conclusion:  Our  study  is an  important  ﬁrst  step  in  deriving  a general  framework  that  combines  disease
dynamics  and  mechanisms  of vaccine  protection  that could  be  used  to  assess  the  impact  of  vaccination
at  a population  level.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Dengue, an arthropod-borne viral disease caused by four distinct
irus serotypes, has become an increasing public health problem.
n estimated 3.9 billion people in 128 countries live in tropical and
ubtropical regions where they are at risk of the disease [1]. Glob-
lly, there are an estimated 390 million dengue infections annually,
f which 96 million result in manifest disease [2]. Symptoms range
rom mild to moderate undifferentiated febrile illness to more
omplex severe clinical manifestations which can lead to death.
espite life-long immunity to the infecting serotype and limited
uration of cross-protection against other serotypes [3,4], severe
engue disease is more often associated with second or subsequent
∗ Corresponding author. Tel.: +33 437377804.
E-mail address: laurent.coudeville@sanoﬁpasteur.com (L. Coudeville).
ttp://dx.doi.org/10.1016/j.vaccine.2015.11.023
264-410X/© 2015 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY license (http://creativecommons.org/licens(http://creativecommons.org/licenses/by/4.0/).
infection with heterologous dengue serotype, hypothesized to be
due to antibody-dependent enhancement of infection by preexis-
ting “cross-enhancing” antibodies [5].
There is no speciﬁc treatment for dengue other than supportive
therapy, and no currently licensed vaccine. A recombinant yel-
low fever-17D–dengue virus, live, attenuated, tetravalent dengue
vaccine (CYD-TDV) has undergone extensive safety and immuno-
genicity assessment [6–12], and is currently in late phase
development. Two, recently completed, landmark, phase III stud-
ies undertaken in ﬁve countries in South East Asia (NCT01373281)
and ﬁve countries in Latin America (NCT01374516) have shown
the vaccine to be effective in reducing symptomatic, virologically-
conﬁrmed dengue. The observed efﬁcacy 28 days after the third
injection (i.e. from month 13 through to month 25 of follow-up)
was 56.5% (95% conﬁdence interval; 43.8–66.4) in the Asian trial
and 60.8% (95% conﬁdence interval; 52.0 to 68.0) in the Latin Amer-
ican trial. In addition, CYD-TDV reduced the rates of severe disease
es/by/4.0/).
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nd associated hospitalizations in both studies, suggesting [13] that
he vaccine has the potential to provide a signiﬁcant public health
eneﬁt [14,15].
Following the successful completion of these phase III studies
ith CYD-TDV, policymakers need evidence on the public health
mpact of vaccination to inform decisions regarding implementa-
ion of country-speciﬁc vaccination strategies/programs. Models
f dengue transmission dynamics, use of which has been recom-
ended by WHO  [16], can provide insights on these important
uestions.
In this paper, we built on a previously developed dengue trans-
ission model [17]. The main objective of the study presented here
as to estimate the key parameters of this model using the large
mount of information collected during the two phase III efﬁcacy
tudies [14,15]. The ﬁrst motivation for these estimations comes
rom the efﬁcacy proﬁles observed during the studies. Differences
ere observed according to serotype, level of dengue severity and
rior exposure to dengue infection. Interpreting these differences
equires a combination of parameters accounting for the under-
ying mechanisms of vaccine protection which can be adequately
epresented with a disease transmission model.
The second important motivation was related to the role of
nteractions between serotypes in dengue dynamics. In a vaccine
rial, vaccine efﬁcacy informs on the risk reduction of developing
he disease upon exposure through a comparison between the inci-
ence observed in the vaccine and control groups. An important
ssumption rests on the independence between disease exposure
ver time (hazard rates) and protection conferred by vaccination
pon exposure. However, this independence does not hold in the
resence of interacting serotypes, where at each point in time, both
he risk of developing infection upon exposure (through cross-
rotection) and the potential risk that this infection leads to a
ymptomatic case (through possible cross-enhancement) is a func-
ion of past exposure to other serotypes. In this case, protection
onferred by vaccination against one serotype inﬂuences future
nfection by other serotypes. This can therefore interfere with the
orrect interpretation of vaccine efﬁcacy in terms of risk reduction
pon exposure required for understanding of the differences in efﬁ-
acy observed across settings or when assessing vaccination impact
t a population level.
A correct assessment of vaccine efﬁcacy in the presence of
nteracting serotypes can in fact be obtained through a sepa-
ate evaluation of hazard rates in the vaccine and control groups
ccounting for these interactions. This was done, in the analysis
resented here, through a transmission model. Such an approach
equires an assessment of dengue exposure since birth. There-
ore, two types of estimation were performed. The ﬁrst focused on
engue exposure from birth to inclusion in the trial, and the second,
he main one, focused on dengue exposure during the trial period.
As such, the parameters estimated relate to efﬁcacy, interaction
etween serotypes and transmission intensity in the ten countries
ncluded in the phase III studies. Using the parameter estimates, we
lso assessed through simulations the long-term direct protection
onferred by the vaccine. This analysis, which is completed by the
esults presented in a companion paper [18], is the ﬁrst step in a
lobal approach aimed at informing on the population-level impact
f dengue vaccination in endemic countries.
. Methods
.1. The mechanistic transmission model
418The analysis presented here builds on a previously developed
eterministic age-structured compartmental model [17] repre-
enting the transmission dynamics of the four dengue serotypes in
uman and mosquito populations. More precisely, we used here a 
cohort version of this model focused on the infection process among
hosts and modiﬁed several assumptions. Notably, we modiﬁed the
representation of vaccine protection by allowing a complete loss
of vaccine protection over time, a decrease in disease severity for
breakthrough cases (i.e. dengue cases among vaccinated subjects)
and a level of vaccine protection dependent on the number of pre-
vious dengue infections. Following Rodriguez-Barraquer et al. [19],
we also simpliﬁed the representation of cross-enhancement. As in
the previous version, we considered a “leaky-type” vaccine [20],
i.e. each vaccinated subject beneﬁts from a partial protection in
case of exposure. The set of equations deﬁning the infection process
among hosts as well the corresponding ﬂow diagram are presented
in detail in supplementary information S1. The other equations of
the model, which are not directly used in the analysis presented
here, can be found in a companion paper [18].
2.2. Clinical and immunological data
Results of the efﬁcacy and safety of CYD-TDV from the two
pivotal phase III efﬁcacy studies have been published previously
[14,15]. In brief, the two studies involved 31,144 children between
the ages of 2 and 16 years of whom 20,771 were assigned CYD-TDV
and 10,373 to control (2:1 ratio). Participants received three doses
of CYD-TDV or placebo at months 0, 6, and 12, and were actively
followed up for any febrile illnesses and assessed for dengue until
month 25 after the ﬁrst study injection. During this time, there
were 1282 virologically-conﬁrmed dengue episodes (574 and 708
episodes in the CYD-TDV and control groups, respectively) and of
these, 161 episodes resulted in hospitalization (57 and 104 episodes
in the two  groups, respectively). The information on the serologi-
cal status at baseline was available for a total of 3927 participants
included in the immunogenicity subsets embedded in the two efﬁ-
cacy studies [14,15].
Two types of estimation were performed from these data.
The ﬁrst focused on dengue transmission prior to the trial and
was based on the immunological subset embedded in each trial.
The immunogenicity subsets provided information on the age-
stratiﬁed serological proﬁle at baseline based on the concentration
of dengue neutralizing antibody measured with the plaque reduc-
tion neutralization test (PRNT50) (see S2.1.1 in Supplementary
information S2). Subjects included in these immunological sub-
sets were divided into 105 cohorts according to country of origin
(Indonesia, Malaysia, Philippines, Thailand, and Vietnam in the
Asian study, and Brazil, Colombia, Honduras, Mexico and Puerto
Rico in the Latin American study) and age at inclusion (2 to 14 years
in the Asian study, and 9 to 16 years in the Latin American study).
For the second estimation, which focused on dengue transmis-
sion during the study period, subjects were also divided by country
of origin and age at inclusion, as well as by vaccine group and
month of enrolment (June to December 2011 in the Asian study,
June 2011 to March 2012 in the Latin American study). A total of
1710 cohorts were considered with 24 months of dengue cases
observed, corresponding to 41,040 cohort months’ observation.
Given its importance from a public health perspective, we used
hospitalization as a proxy for dengue severity.
2.3. Estimation method
All estimations performed were based on a sequential Monte
Carlo (SMC) algorithm using the method proposed by Toni et al.
[21], which extends from the one of Sisson et al. [22]. Starting
from prior distributions, parameter values were iteratively pro-
–34 (2016) 641 64257posed through sampling based on SMC. Final values of parameters
(forming the posterior distribution) were those for which model
predictions were close to the observed clinical data. This method
provides ﬂexibility in the deﬁnition of the distance function that
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accineeasures the proximity between predictions and observations. In
ur case, this distance was a negative multinomial likelihood. This
nabled us to use the Deviance Information Criterion (DIC) to assess
he quality of the ﬁt associated to each of the candidate models [23].
lternatively, we considered the distribution of −2* log-likelihood
or this assessment. The posterior median value and the 95% cred-
ble interval (95% CI) were used to present the results obtained for
stimated parameters.
The ﬁrst estimation considered the level of dengue exposure
mong subjects from birth to study enrolment and provided an
stimation of the country- and serotype-speciﬁc annual force of
nfection from 1995 to 2010 for Latin American, and from 1997
o 2010 for Asia. As with Ferguson et al. and Imai et al. [24,25],
e used PRNT50 data, distinguished between naïve, monotypic
nd multitypic immunological proﬁles and considered a multi-
omial likelihood. This estimation also enabled us to assess the
erotype-speciﬁc basic reproduction numbers (R0) for each of the
0 countries.
Six scenarios of vaccine efﬁcacy were tested in the second esti-
ation, by ﬁtting to data observed during the trials (Table 1).
epending on the scenario, 4 to 22 parameters related to vaccine
fﬁcacy were estimated. Parameters included the relative risk of
eveloping disease upon exposure depending on the serotype and
he serological proﬁle of the subject (rklms , where s is the serotype,
nd k, l and m symbolize the dengue immune status for the other
erotypes); the reduction of severity after infection by serotype s in
ase of disease among vaccinated (svs), and the waning of vaccine
rotection over time (wklms ).
Two main scenarios for the interactions between the four
engue serotypes were considered. In the ﬁrst scenario, inter-
ctions between serotypes were limited to temporary cross-
rotection against any heterotypic infection for a limited period
f time after a dengue infection (Scenario CP—“cross-protection
nly”). In this scenario, the only estimated parameter related to
erotype interactions was the average duration of cross-protection
εH). The second scenario included, in addition to cross-protection,
 differential risk of developing symptomatic dengue between
rimary, secondary, tertiary and quaternary infections (Scenario
PE—“cross-protection and cross-enhancement”). This allowed,
L. Coudeville et al. / Vesides the average duration of cross-protection, the estimation
f three additional parameters: the relative risk, compared to
rimary infection, of developing a hospitalized and ambulatory
ase upon secondary infection (zs(2), zm(2)) and of developing
able 1
ix vaccine efﬁcacy proﬁles assessed for the two  scenarios of serotypes interaction, CP
orresponding DIC.
Scenario 1 Scenario 2 Scenario3
Efﬁcacy by serotype Serotype-speciﬁc Serotype-speciﬁc Serotype-s
Efﬁcacy for naïve
subjects
Same efﬁcacy as for
primed
Lower efﬁcacy for
naïve
Lower efﬁ
naïve
Efﬁcacy against
hospitalizations
Same as ambulatory
cases
Same as ambulatory
cases
Higher for
hospitaliz
Increase in efﬁcacy
with doses
No increase No increase No increas
Waning of vaccine
efﬁcacy
No waning No waning No waning
Accelerated exposure
to secondary
infection$
No No No 
Deviance
information
criterion (DIC)*
Scenario CP 21,123 21,091 21,087 
Scenario CPE 21,158 21,108 21,101 
* Each cell contains the DIC value for each of the 12 scenarios tested (e.g. the top left ce
$ Vaccination plays a role similar to natural infection and exposes those who were ser
ho  were pre-exposed to natural infection to the same level of risk associated with post-a dengue case upon tertiary or quaternary infection (assumed to
be zs(3) = zm(3) = zs(4) = zm(4)). For each of the 10 countries con-
sidered, we  also estimated the force of infection, seasonality in
transmission and proportion of dengue cases leading to hospital-
ization.
2.4. Comparison with routine surveillance data
We performed a qualitative assessment of the estimation by
comparing observed and estimated attack rates in the control
group of the vaccine trials with available information from national
routine surveillance systems. For these comparisons, we used
surveillance data on suspected dengue cases corresponding to the
age groups and areas in the countries in which study sites were
located and to the study period (June 2011 to December 2013 for the
Asian countries and June 2011 to March 2014 for the Latin American
countries). To account for under-reporting in surveillance systems
[26], we  rescaled reported incidence rates to match the observed
attack rates during the trials.
2.5. Evolution of vaccine efﬁcacy over time
Finally, using the posterior distribution of estimated parame-
ters, we ran Monte Carlo simulations to assess the evolution of
vaccine efﬁcacy over 20 years for different scenarios of vaccine
efﬁcacy at different ages and serological status at the time of
vaccination. We  compared simulated attack rates for vaccinated
and non-vaccinated subjects to obtain a measure corresponding to
observed efﬁcacy.
3. Results
3.1. Country-speciﬁc basic reproduction numbers (R0)
The observed and estimated age-stratiﬁed seroprevalence data
at baseline per country are presented in supplementary informa-
tion S2 (Figures 4, 6, 8, 10, 12, 14, 16, 18, 20, 22). In general,
we observed a good ﬁt across all countries with only a few
points outside the estimated 95% CI. The estimated country-speciﬁc
serotype-speciﬁc force of infection prior to the study period is also
 
–34 (2016) 641 64257 6419summarized in supplementary information S2 (Figs. 3, 5, 7, 9, 11, 13,
15, 17, 19, and 21). Combined with the estimated force of infection
during the trial based on the model exhibiting the best ﬁt we were
able to calculate the serotype-speciﬁc reproduction numbers (R0)
 (cross protection only) and CPE (cross-protection and cross-enhancement) and
 Scenario4 Scenario 5 Scenario 6
peciﬁc Serotype-speciﬁc Serotype-speciﬁc Serotype-speciﬁc
cacy for Lower efﬁcacy for
naïve
Lower efﬁcacy for
naïve
Lower efﬁcacy for
naïve
ed cases
Higher for
hospitalized cases
Higher for
hospitalized cases
Higher for
hospitalized cases
e Increase in efﬁcacy
with doses for
naïve
Increase in efﬁcacy
with doses for
naïve
Increase in efﬁcacy
with doses for
naïve
 No waning Waning efﬁcacy
after each dose
Waning efﬁcacy
after each dose
No No Yes
21,085 21,080
21,092 21,095 21,085
ll corresponds to scenario CP1, the ﬁrst bottom left to scenario CPE1, etc).
onegative to the same level of risk associated with secondary infection and those
secondary infections.
    
 
Table 2
Serotype-speciﬁc basic reproduction number (R0) estimates and seasonal variation of dengue transmission in the 10 countries participating in the phase III efﬁcacy trials
(Posterior median value and 95% CI calculated from estimated annual force of infection prior and during the trial—scenario CP5).
Dengue 1 Dengue 2 Dengue 3 Dengue 4 Intra-annual variation in
transmission (%)
Month with peak
transmission
Post. median [95% CI] Post. median [95% CI] Post. median [95% CI] Post. median [95% CI]
Brazil 2.7 [2.3;3] 3 [2.6;3.5] 3.3 [2.8;3.8] 2 [1.9;2.1] ±96 April
Colombia 4.2 [3.8;4.7] 2.9 [2.5;3.3] 3.3 [3;3.7] 1.9 [1.7;2.2] ±79 April
Honduras 2.4 [2.1;2.6] 3.3 [2.9;3.7] 3.2 [2.9;3.4] 1.9 [1.7;2.1] ±80 September
Mexico 2.3 [2.1;2.5] 2.4 [2.3;2.6] 1.9 [1.7;2] 1.3 [1.2;1.3] ±99 September
Puerto Rico 2.5 [2.3;2.7] 2.7 [2.3;3] 2.2 [2;2.5] 1.2 [1.2;1.3] ±84 July
Indonesia 3.1 [2.7;3.5] 3.6 [3.2;4.1] 2.7 [2.4;3] 2.2 [1.9;2.4] ±80 March
Malaysia 2.2 [1.9;2.6] 2.5 [2.1;2.8] 1.8 [1.6;2.1] 1.9 [1.7;2.2] ±45 January
Philippines 3.9 [3.5;4.3] 3.2 [2.8;3.5] 2.1 [2;2.3] 2.4 [2.2;2.6] ±41 August
Thailand 3.9 [3.4;4.5] 5.2 [4.6;5.9] 3.4 [2.9;3.8] 2.2 [1.9;2.6] ±47 June
Vietnam 2.8 [2.5;3.3] 3 [2.6;3.4] 2 [1.7;2.3] 3 [2.7;3.3] ±74 August
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Minimum 2.2 2.4 1.8 
Maximum 4.2 5.2 3.4 
cross all ten countries (see Table 2 and Table 26 in Supplementary
nformation S2 for results with another vaccine efﬁcacy scenario).
0 was greater than 1 for all serotypes (range 1.2 to 5.2) suggest-
ng that all dengue serotypes contribute to dengue transmission in
hese countries. Overall, higher R0 were observed for Dengue 2 fol-
owed by Dengue 1 whereas the lowest R0 was observed for Dengue
 in seven countries including the ﬁve Latin American countries.
hailand was the country with the highest reproduction numbers
hereas in three countries (Mexico, Puerto Rico and Malaysia) the
edian R0 was below 3 for all serotypes.
.2. Evolution of monthly dengue incidence in the control group
The monthly dengue incidence for the observed cases, esti-
ated cases and those notiﬁed to the national surveillance systems
re summarized in supplementary information S2 for all countries
Section S2.2.3.6 and S2.2.4.7 for scenario CP and CPE, respec-
ively). In the control group, we compared observed and estimated
ncidence rates with rescaled surveillance data. In general, the esti-
ated seasonality and year-to-year variation were broadly aligned
ith national surveillance reports indicating that data collected
uring the trial were representative of dengue dynamics in the
egion and that the estimation performed was able to reproduce
nderlying seasonality.
.3. Interaction between serotypes
Estimated parameters for the two scenarios of interaction with
erotypes (CP and CPE) are summarized in Table 3. The two  sce-
arios differed with respect to the duration of cross-protection
ith a lower value for scenario CP (7 months [95% CI, 6–9] versus
5 months [95% CI, 11–18] for scenario CPE). In scenario CPE, we
able 3
arameter estimates and goodness-of-ﬁt measures in the two  scenarios of serotypes inte
Scenarios of interaction be
Cross protection only (scen
Posterior median [95% CI] 
Average duration of cross-protection (months) 6.99 [6.1;9.1] 
Increased risk of severe case (2nd infection)$ 1 
Increased risk of mild case (2nd infection)$ 1 
Increased risk of case (3rd–4th infection)$ 1 
Deviance Information Criterion 21,080.3 
-2*  Log-likelihood 21,059 [21,053;21,067] 
* Results presented derived from models corresponding to reference scenarios for vacc
$ Compared to the risk associated with primary infection.2.0 – –
1.2 – –
3.0 – –
identiﬁed a moderate increased relative risk of symptomatic illness
in case of secondary infection and no major difference between
hospitalized (1.88) and ambulatory cases (1.72).
Both scenarios were relatively similar in their ability to ﬁt to
observed data as indicated by very similar log-likelihoods. How-
ever, the DIC was  lower for scenario CP. This can be related to the
use of fewer parameters in scenario CP (1 versus 4 for serotype
interactions) since the DIC accounts for the effective number of
parameters.
3.4. Vaccine efﬁcacy
The detailed results of the estimations performed can be found
in supplementary information S2 (S2.2.3 for interaction scenario
CP, S2.2.4 for interaction scenario CPE) and corresponding DIC are
presented Table 1. The hierarchy of vaccine proﬁles in terms of DIC
was similar for scenario CP and CPE. The ﬁt to observed data was
signiﬁcantly improved when considering differences in efﬁcacy
between subjects previously exposed or not exposed to dengue
infection prior to vaccination (pre-exposed or naïve). The difference
in DIC values between scenario CP1 and CP2 was −32 and between
scenario CPE1 and CPE2, −50. Further improvement in data ﬁt was
obtained when accounting for differences in severity (scenario 3)
and increase in efﬁcacy with doses for naïve subjects (scenario 4).
There was  no scenario with an increase in efﬁcacy with doses for
all subjects that improved data ﬁt compared to scenario 4.
The estimation performed allowed us to go a step further by
including waning of vaccine protection in the estimation. Both
scenarios CP and CPE led to marked differences in the waning of
vaccine protection for naïve and pre-exposed subjects. The esti-
mated annual waning rate was  55% [95% CI, 15–93] for naïve and
5% [95% CI, 0–15]) for pre-exposed subjects in scenario CP5. The
raction assessed.
tween serotypes*
ario CP) Cross-protection and cross-enhancement (scenario CPE)
Posterior median [95% CI]
15.30 [11.5;17.8]
1.88 [1.4;2.4]
1.72 [1.5;2.0]
0.47 [0.12;0.8]
21,085.1
21,059 [21,053;21,063]
ination (respectively scenario CP5 and scenario CPE6).
F (95% C
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L. Coudeville et al. / Vaccine –34 (2016) 641 64257 6421ig. 1. Observed and estimated efﬁcacy [median value with upper/lower bounds 
gainst all dengue cases by serotype and overall for scenario CP5 and scenario CPE6
nclusion of waning of vaccine protection signiﬁcantly improved
he ﬁt for scenario CP (the DIC was lower (-5) for scenario CP5
ompared to scenario CP4).
Finally, we considered a scenario where vaccination was likely
o generate cross-enhancement. More speciﬁcally, in this scenario,
e considered that vaccination played a role similar to natural
nfection by exposing naïve subjects directly to the same level of
isk associated with secondary infection. Similarly, we  considered
hat pre-exposed subjects when vaccinated faced the same level of
isk associated with post-secondary infection (tertiary instead of
econdary). As in natural infection, this was expected to occur once
rotection (here vaccine-induced) had waned. This scenario led to
 decrease in the DIC for scenario CPE (21,085 for scenario CPE6
ersus 21,092 for scenario CP4) although the DIC remained higher
or scenario CPE6 compared to scenario CP5 (Table 1).
The overall quality of data ﬁt remained similar for scenario CP5
nd CPE6 as indicated by the results of observed and estimated efﬁ-
acy in Fig. 1. The difference in DIC was probably due to the fewer
umber of estimated parameters in scenario CP5. In terms of the
evel of primary efﬁcacy for each proﬁle (Table 4), scenario CPE6 led
verall to a slightly higher efﬁcacy notably for naïve subjects com-
ared to scenario CP5. This can be seen as a direct consequence of
he consideration of vaccine-induced cross-enhancement in sce-
ario CPE6.
Both scenarios CP5 and CPE6 led to a good ﬁt to observed efﬁcacy
onsidering serotype-speciﬁc efﬁcacy or efﬁcacy against hospital-
zed cases (Fig. 1). With respect to country-speciﬁc results, both
cenarios also performed similarly well for all except 3 countries
Malaysia, Mexico and Vietnam). Although the ﬁt was  not fully
ccurate for efﬁcacy with doses, scenario CPE6 captured slightly
etter than scenario CP5 the differences between doses. The two
cenarios captured increase in efﬁcacy with age but none of the
cenarios fully reproduced the lower efﬁcacy observed in the 2–5
ear age group. Since the underlying transmission model was  not
tochastic, estimation results did not fully capture the random
ariation in the observed efﬁcacy induced by a limited number of
bservations in some of the subgroups considered (Fig. 1)..5. Evolution of vaccine efﬁcacy over time
The two reference scenarios CP5 and CPE6 differ with respect
o the evolution of vaccine efﬁcacy over time. The results forI)] according to dose, country, age group, against hospitalized dengue cases, and
Malaysia presented in Fig. 2a and d highlight that the main dif-
ference pertains to the evolution of vaccine efﬁcacy over time for
young children between 2 and 5 years after vaccination. Whereas
a steady decrease is expected for scenario CP5, vaccine-induced
cross-enhancement considered in scenario CPE6 was  likely to gen-
erate a sharp decrease in efﬁcacy once the initial protection had
waned, leading in some scenarios to a negative efﬁcacy for a period
of time. This result is mainly driven by the consequence of vac-
cination for naïve subjects that face an accelerated exposure to
secondary infection with this scenario. This can be seen with the
results presented in Fig. 2 speciﬁcally for this category (Fig. 2c and
f). This drop is not visible in case of vaccination of children aged 9
years (Fig. 2b and e), an age at which the proportion of seronegative
children is lower. Results reported in Supplementary information
S2 showed similar evolution whatever the country considered (Sec-
tion S2.2.4.7).
Over 20 years, the median reduction of dengue risk induced by
the direct protection conferred by the vaccine ranged from 24% to
47% according to country for scenario CP5 and from 34% to 54%
for scenario CPE6 (Fig. 3). Scenario CPE6 mainly generates more
uncertainty in the following 2 to 5 years after vaccination for young
children. Overall, especially given the higher estimated efﬁcacy for
subjects when seropositive (Table 4), scenario CPE6 leads to similar,
if not larger, cumulated vaccination beneﬁts than scenario CP5.
4. Discussion
We estimated in this paper the key parameters of a previously
developed mathematical model [17] related to vaccine efﬁcacy,
interaction between serotypes and transmission intensity using
data collected from two recently completed phase III studies with
CYD-TDV [14,15]. The estimation performed ﬁrst enabled us to
characterize dengue transmission intensity in the 10 countries
involved in these two trials. This conﬁrmed that the four dengue
serotypes contribute to dengue transmission in these countries
with the following hierarchy (dengue serotype 2, 1, 3 and 4), but
with some differences across countries (see Table 2). Interestingly,
although not fully aligned, the results for the countries assessed in
our study are consistent with those reported recently by Imai et al.
[25] (Thailand and Indonesia) and Rodriguez-Barraquer et al. [27]
(Thailand). Of note, our estimation was based on data collected at
study sites selected to participate in the efﬁcacy trials because of
 Table 4
Scenario CP5 and CPE6 according to serotype, dose schedule, status at baseline (pre-exposed or naïve), severity (ambulatory or hospitalized cases) and waning. Data shown
as  median values with upper/lower bounds (95% CI).
Scenario CP5
Ambulatory cases Hospitalized cases
Pre-exposed Naive Pre-exposed Naive
Post.
Median (%)
95% CI Post.
Median (%)
95% CI Post.
Median (%)
95% CI Post.
Median (%)
95% CI
Dengue 1
1 dose 67 [59,76] 19 [2,40] 76 [78,78] 41 [49,45]
2  doses 67 [59,76] 31 [3,63] 76 [78,78] 50 [49,66]
3  doses 67 [59,76] 39 [4,71] 76 [78,78] 56 [50,73]
Dengue 2
1 dose 59 [49,69] 8 [0,25] 72 [76,74] 37 [52,36]
2  doses 59 [49,69] 17 [1,49] 72 [76,74] 44 [53,57]
3  doses 59 [49,69] 26 [2,61] 72 [76,74] 50 [53,67]
Dengue 3
1 dose 81 [75,87] 26 [2,56] 84 [84,87] 38 [39,57]
2  doses 81 [75,87] 50 [6,84] 84 [84,87] 58 [41,84]
3  doses 81 [75,87] 73 [30,87] 84 [84,87] 77 [56,87]
Dengue 4
1 dose 91 [84,97] 19 [1,52] 93 [93,97] 43 [56,54]
2  doses 91 [84,97] 26 [2,67] 93 [93,97] 47 [56,68]
3  doses 91 [84,97] 41 [3,85] 93 [93,97] 58 [57,85]
Annual waning rate—Naive 55.1 [15,93]
Annual waning rate—Pre-exposed 5.0 [0,15]
−2* Log-likelihood 21,058.8 [21053,21067]
Deviance Information criterion 21,080.3
Scenario CPE6
Ambulatory cases Hospitalized cases
Pre-exposed Naive Pre-exposed Naive
Post.
median (%)
95% CI Post.
median (%)
95% CI Post.
median (%)
95% CI Post.
median (%)
95% CI
Dengue 1
1 dose 71 [63,79] 13 [1,45] 83 [87,82] 49 [66,53]
2  doses 71 [63,79] 36 [2,73] 83 [87,82] 63 [67,77]
3  doses 71 [63,79] 55 [7,79] 83 [87,82] 74 [68,82]
Dengue 2
1 dose 67 [56,76] 7 [0,27] 81 [87,78] 47 [71,33]
2  doses 67 [56,76] 14 [1,45] 81 [87,78] 51 [71,49]
3  doses 67 [56,76] 22 [1,57] 81 [87,78] 56 [71,61]
Dengue 3
1 dose 84 [77,89] 18 [1,53] 87 [91,89] 36 [60,54]
2  doses 84 [77,89] 33 [2,78] 87 [91,89] 48 [61,78]
3  doses 84 [77,89] 68 [11,89] 87 [91,89] 75 [64,89]
Dengue 4
1 dose 89 [83,95] 34 [3,69] 93 [92,95] 54 [56,70]
2  doses 89 [83,95] 45 [4,81] 93 [92,95] 62 [56,81]
3  doses 89 [83,95] 58 [6,89] 93 [92,95] 71 [57,90]
Annual waning rate—Naive 60.5 [15,97]
Annual waning rate—Pre-exposed 3.5 [0,11]
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Deviance Information criterion 21,085
engue endemicity in their region. The results obtained are there-
ore more directly representative of these regions than the entire
ountry.
With respect to interaction between serotypes, we obtained rel-
tively similar ﬁt to the observed data with a scenario considering
nly short-term cross-protection after a dengue infection (scenario
P5) and a scenario combining cross-protection with increased
isk in case of secondary infection (scenario CPE6). Interactions
etween serotypes have been the subject of a number of publica-
ions in the dengue ﬁeld with contrasting results [16]. Although
omprehensive, the datasets used in our analysis were not ide-
lly suited to end this debate. We,  in fact, conﬁrm the ﬁnding of
ur previous publication that different representations of inter-
ction between serotypes are likely to represent observed data
17]. With respect to the duration of cross-protection, the two[21053,21063]
scenarios differ with a lower value for scenario CP than CPE (7
months versus 15 months). The link between duration of cross-
protection and level of increased symptomatic illness in case of
secondary infection has already been noted by Mizumoto et al. [28].
These durations, notably for scenario CP, are shorter than the results
published recently (1 to 3 years [29,30]) but higher than the semi-
nal publication from Sabin (6 months [31]). In scenario CPE, we
identiﬁed a moderate increased risk of symptomatic infection in
case of secondary infection and no major difference in the relative
risk for hospitalized (1.9) and ambulatory cases (1.7). This result is
at the low end of data reviewed by Mizumoto et al. [28] (from 1.9
to 14.3 for relative risk of symptomatic illness in case of secondary
infection). A number of factors, may, in part, explain this difference,
starting with the active surveillance performed during the phase
III trials and the differing methods for case detection used in the
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L. Coudeville et al. / Vaccine –34 (2016) 641 64257 6423ig. 2. Monthly reduction of dengue cases over 20 years for subjects vaccinated at 
engue  before vaccination (c and f)—Results for Malaysia, as an example.
tudies reviewed by Mizumoto et al. [28]. The age groups con-
idered in the trials (2–14 years and 9–16 years) can also play a
ole since dengue symptomaticity has been shown to vary with
ge [32,33]. To fully interpret these results, it can also be useful
o determine how the relative risks we estimated translate into the
roportion of symptomatic cases due to secondary infections at the
opulation level. This was done in a subsequent companion paper
18].
The estimation performed led to a vaccine efﬁcacy proﬁle char-
cterized by differences in efﬁcacy per serotype, increased efﬁcacy
or seropositive subjects, increased efﬁcacy against severe forms,
nd increased efﬁcacy with doses for naïve individuals. These
esults are consistent with the ﬁndings reported both in the Asian
nd Latin American studies [14,15] and were observed for the
wo scenarios of serotype interactions considered. We  were also
ble to account for waning of vaccine protection. The data used
re arguably limited to the 25 months of the active surveillance
mplemented in the two phase III studies, but were nonetheless
ufﬁcient for us to detect a marked difference in vaccine protection
aning between naïve (55% [95% CI, 15–93]) and pre-exposed sub-ects (5% [95% CI, 0–15]). This waning, however, does not entirely
ictate the overall duration of protection since the status of vacci-
ated subjects’ changes as they experience a dengue infection. We
Fig. 3. Cumulative reduction of dengue cases over 20 years for subjects vyears (a and d) and 9 years (b and e), and for 9-year-old subjects never exposed to
ﬁnally considered a scenario (scenario CPE6) with vaccine-induced
cross-enhancement along the lines of the scenarios explored by
Rodriguez-Barraquer et al. [34]. This scenario was not associated
with the best ﬁt, based on the DIC criterion, but led to an overall
similar quality of ﬁt compared to the other reference scenario. The
results obtained cannot, therefore, rule it out as a possible scenario
for explaining mechanisms of vaccine protection.
Although the two scenarios are similar in their ability to
reproduce data observed during the phase III studies, they differ
regarding the evolution of vaccine efﬁcacy over time. More speciﬁ-
cally, scenario CPE6 generated wide uncertainty in vaccine efﬁcacy
following 2 to 5 years after vaccination for naïve subjects or young
children, where a signiﬁcant proportion of subjects were naïve
when vaccinated. Nevertheless, in the long term (20 years), this
scenario produces a similar if not larger reduction in dengue cases
than scenario CP5, including for naïve subjects. Vaccine-induced
cross-enhancement considered here essentially accelerates expo-
sure to secondary infection for naïve subjects, and as such, its main
impact would be on modifying the time at which a subject develops
dengue, with a lower impact on the overall risk. It is noteworthy
that age-speciﬁc differences in the risk of developing dengue dis-
ease are likely to inﬂuence this result. Current evidence [32,33],
however, indicates an increase in symptomaticity with age may
accinated at age 9 years for scenario CP5 (a) and scenario CPE6 (b).
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ossibly limit the negative consequences of accelerated exposure
o secondary infection.
Dengue dynamics inﬂuence the way vaccine-induced cross-
nhancement impacts the evolution of vaccine efﬁcacy over time.
ts impact is more visible when the level of dengue incidence
hanges between the time vaccine recipients get vaccinated and
ose their protection (e.g. switch from low to high force of infec-
ion). The inﬂuence of dengue circulation in the previous years on
he interpretation of epidemiological observations is well known.
revious dengue seasons have, for instance, been identiﬁed as
n epidemiological risk factor for explaining the observed rate of
napparent infections [35]. Our results for vaccine-induced cross-
nhancement cannot be compared directly with those obtained by
odriguez-Barraquer et al. [34] since we did not consider the exact
ame mechanisms, their focus was on dengue serotype 2 and they
id not explicitly considered the results of the two phase III studies
ith CYD-TDV as they were not available at the time of their anal-
sis. However, we share the same conclusion that vaccine-induced
ross-enhancement does not necessarily imply that vaccination is
etrimental. Moreover, our analysis of vaccine efﬁcacy over time
as limited to direct effects and did not include the potential posi-
ive effects associated to indirect protection [36]. The contribution
f indirect protection will be addressed more directly in a follow-up
aper focused on the impact of dengue vaccination at the popula-
ion level [18].
Our study has a number of limitations linked ﬁrst to the data
sed. To keep the estimation tractable, we used a cohort-based
pproach and not an individual-based approach that could have
elped to better characterize dengue status notably for subjects
nown to have experienced dengue during the trial. We also
ssumed a similar exposure to dengue for all subjects within each
ountry, whereas some differences were observed between differ-
nt sites in the same country. In addition, we used hospitalizations
s a proxy for severe outcomes related to dengue mainly because of
ts importance from a public health perspective. However, although
ospitalization rates reﬂect dengue severity, they may  also be inﬂu-
nced by differences in clinical practice patterns.
A wide range of additional scenarios of serotype interactions
ould also have been tested. For instance, we assumed that the
uration of cross-protective immunity following natural infection
ould be the same, irrespective of dengue serotype or sever-
ty. Anderson et al. [30] reported differences in the duration of
ross-protection for clinical and subclinical infections. In addition,
e did not speciﬁcally differentiate between tertiary and quater-
ary infections when considering the probability of symptomatic
nfection. The nature of available information was a limiting fac-
or. Although comprehensive, the datasets used in our analysis
o not provide detailed serological information for all subjects
nd longitudinal information over a long period of time. Thus,
e had limited ability to differentiate between very detailed rep-
esentations of serotype interactions. We,  therefore, preferred to
oncentrate the analysis on a limited number of scenarios capturing
he state of knowledge on the topic (i.e. the consideration of both
ross-protection and cross-enhancement). Besides, the two main
cenarios selected led overall to a similar quality of ﬁt to observed
ata.
Regarding vaccine efﬁcacy, the scenarios considered enabled
s to assess the main factors related to vaccine protection includ-
ng vaccine-induced cross-enhancement. We,  however, limited our
nalysis to a leaky-type vaccine (partial immunity for all subjects)
nd did not consider all-or-nothing protection (full protection of
 subset of vaccinated subjects) [20]. This can nevertheless be
L. Coudeville et al. / Vac424een as conservative with respect to vaccination beneﬁts over time
ince, contrary to all-or-nothing protection, it accounts for possi-
le vaccine failure following repeated exposure. Similarly, since our
nalysis was only based on the 25 months of active follow-up, theestimated waning in vaccine efﬁcacy needs to be revisited as more
information becomes available.
Our estimation of vaccine efﬁcacy was  able to partially but not
fully reproduce the differences in efﬁcacy between age groups. This
could be improved by the consideration of an age effect indepen-
dent from the serological status. We  also did not fully capture the
observed evolution of efﬁcacy with doses. At this level, analyses that
can be performed on the additional beneﬁt provided by the second
and third dose are nevertheless limited since almost all participants
in the vaccine studies ultimately received three doses.
We used the SMC  algorithm developed by Toni et al. [21].
Recently, a number of Bayesian methods have been proposed to
estimate parameters of transmission models [37], including Monte
Carlo Marko Chains methods with data augmentation, different
SMC  techniques or a combination of these methods like particle
MCMC  [38]. Each method comes with strengths and weaknesses
regarding its efﬁciency, suitability to the problem at hand and also
with respect to computational aspects. One important advantage
of the SMC  approach used here is that it can be easily parallelized.
That proved to be critical considering the large number of obser-
vations included in our analysis that required intensive computer
processing time (>100,000 h). Another example of the use of the
method developed by Toni et al. [21] for estimating the parameters
of a transmission model can be found in Brooks-Pollock et al. [39]
who also dealt with a large dataset in their analysis.
Our ability with this approach to use the detailed information
collected during the two large phase III studies to estimate key
parameters in our transmission model for ten countries is the main
strength of the work presented here. It allowed us to reconcile
the complex dynamics of dengue with a detailed analysis of fac-
tors impacting vaccine efﬁcacy. It also provided insights beyond
efﬁcacy on the transmission intensity of dengue in the ten par-
ticipating countries. To our knowledge, examples of estimation of
the parameters of a transmission model directly from the results
of large-scale multi-country trials are scarce. Our analysis, how-
ever, did not address all uncertainties regarding the efﬁcacy of
CYD-TDV. The ongoing longitudinal surveillance for an additional
4 years in both these phase III studies will help better establish
the long-term beneﬁts of vaccination. Besides, the recent publi-
cation by Hadinegoro et al. [40] of the ﬁrst year results of this
longitudinal surveillance (year 3 from start of vaccination) has
led to a number of important observations. The results for this
speciﬁc year indicated a lower incidence of hospitalization for
dengue for children aged ≥9 years at the time of vaccination (rel-
ative risk 0.5 [95% CI, 0.29–0.86] but also a higher incidence of
hospitalization for children aged <9 years when vaccinated (rel-
ative risk 1.58 [95% CI 0.83–3.02]). Although additional analyses
are required to further validate this point, these results showed
some consistency with the results evidenced here for scenario CPE6
i.e. uncertainty in efﬁcacy 2 to 5 years after vaccination for young
and naïve children despite positive long term beneﬁts of vaccina-
tion.
In conclusion, our study forms an important ﬁrst step in deriving
a general framework that combines disease dynamics and mech-
anisms of vaccine protection that can be used to assess the public
health impact of dengue vaccination. It has provided us with a bet-
ter understanding of the heterogeneity in the efﬁcacy data observed
which can have important implications for epidemiological projec-
tions. This is addressed in the follow-up paper focused on the public
health impact expected from the implementation of vaccination
programs in endemic countries.
–4 (2016) 641 64257Role of the funding source
Funding for this study was provided by Sanoﬁ Pasteur. The spon-
sor participated in all operational aspects of this modelling study,
i
r
C
w
d
r
C
P
P
A
p
H
t
X
c
p
W
F
m
A
t
0
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
accinencluding data collection, statistical analyses, and writing of the
eport.
ontributors
LC conceived the analysis and designed the estimation method
ith EV. LC and NB performed the analyses. All authors discussed
ata analyses and interpretation, helped to draft and critically
evise the manuscript, and approved the ﬁnal version submitted.
onﬂict of interest statement
Laurent Coudeville and Nicolas Baurin are employees of Sanoﬁ
asteur.
Elisabeta Vergu received neither fees nor funding from Sanoﬁ
asteur for this study.
cknowledgements
Editorial assistance with the preparation of this manuscript was
rovided by Richard Glover, in Science Communications, Springer
ealthcare. Funding for this assistance was provided by Sanoﬁ Pas-
eur. We  thank our Sanoﬁ Pasteur colleagues Luc Gauthier and
avier Le Valliant for their help in accessing the high performance
omputing platform and parallelizing the code used for the results
resented in this manuscript. We  are also very grateful to Jo-Ann
est for her management of the preparation of this manuscript.
inally, we would also like to acknowledge the surveillance system
anagers who kindly provided access to their data.
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.vaccine.2015.11.
23.
eferences
[1] World Health O. Dengue and dengue haemorrhagic fever, fact sheet No. 117;
2015. 〈h*ttp://ww*wwhoint/mediacentre/factsheets/fs117/en/〉.
[2] Bhatt S, Gething PW,  Brady OJ, Messina JP, Farlow AW,  Moyes CL,
et  al. The global distribution and burden of dengue. Nature 2013;496:
504–7.
[3] Murray NE, Quam MB,  Wilder-Smith A. Epidemiology of dengue: past, present
and future prospects. Clin Epidemiol 2013;5:299–309.
[4] OhAinle M,  Balmaseda A, Macalalad AR, Tellez Y, Zody MC,  Saborio S, et al.
Dynamics of dengue disease severity determined by the interplay between viral
genetics and serotype-speciﬁc immunity. Sci Transl Med  2011;3:114ra28.
[5] Simmons M,  Teneza-Mora N, Putnak R. Advances in the development of vac-
cines for dengue fever. Vaccine: Dev Ther 2012;2:1–14.
[6] Tran NH, Luong CQ, Vu TQH, Lang J, Vu QD, Bouckenooghe A, et al. Safety
and immunogenicity of recombinant, live attenuated tetravalent dengue vac-
cine  (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin
2012;3:1000162.
[7] Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, et al.
Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-
TDV) in individuals aged 2–45 y: Phase II randomized controlled trial in
Singapore. Hum Vaccines Immunother 2012;8:1259–71.
[8] Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, et al.
Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds
previously vaccinated against yellow fever: randomized, controlled, phase II
study in Piura, Peru. Vaccine 2012;30:5935–41.
[9] Morrison D, Legg TJ, Billings CW,  Forrat R, Yoksan S, Lang J. A novel tetravalent
dengue vaccine is well tolerated and immunogenic against all 4 serotypes in
ﬂavivirus-naive adults. J Infect Dis 2010;201:370–7.
10] Poo J GF, Forrat R, Zambrano B, Lang J, Dayan GH. Live-attenuated tetravalent
L. Coudeville et al. / Vdengue vaccine in dengue-naive children, adolescents, and adults in Mexico
City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr
Infect Dis J 2011;30:e9–17.
11] Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P,
Suvannadabba S, et al. Protective efﬁcacy of the recombinant, live-attenuated,
[
[CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, con-
trolled phase 2b trial. Lancet 2012;380:1559–67.
12] Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, et al. Live-
attenuated, tetravalent dengue vaccine in children, adolescents and adults
in  a dengue endemic country: randomized controlled phase I trial in the
Philippines. Vaccine 2011;29:3863–72.
13] Villar L, Dayan GH, Arredondo-García JL, Rivera DM,  Cunha R, Deseda C, et al.
Efﬁcacy of a tetravalent dengue vaccine in children in Latin America. N Engl J
Med  2015;372:113–23.
14] Capeding MR,  Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua
MN,  et al. Clinical efﬁcacy and safety of a novel tetravalent dengue vaccine in
healthy children in Asia: a phase 3, randomised, observer-masked, placebo-
controlled trial. Lancet 2014;384:1358–65.
15] Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM,  Cunha R, Deseda C, et al.
Efﬁcacy of a tetravalent dengue vaccine in children in Latin America. N Engl J
Med  2015;372:113–23.
16] Group W-VDVM. Assessing the potential of a candidate dengue vaccine with
mathematical modeling. PLoS Negl Trop Dis 2012;6:e1450.
17] Coudeville L, Garnett GP. Transmission dynamics of the four dengue serotypes
in  southern Vietnam and the potential impact of vaccination. PLoS ONE
2012;7:e51244.
18] Coudeville L, Baurin N, L’azou M,  Guy B. Potential impact of dengue vaccina-
tion: insights from two large-scale phase III trials with the tetravalent dengue
vaccine. Vaccine. Submittted.
19] Rodriguez-Barraquer I, Mier-y-Teran-Romero L, Burke DS, Cummings DA. Chal-
lenges in the interpretation of dengue vaccine trial results. PLoS Negl Trop Dis
2013;7:e2126.
20] Halloran ME,  Haber M,  Longini Jr IM,  Struchiner CJ. Direct and indirect effects
in  vaccine efﬁcacy and effectiveness. Am J Epidemiol 1991;133:323–31.
21] Toni T, Welch D, Strelkowa N, Ipsen A, Stumpf MP. Approximate Bayesian com-
putation scheme for parameter inference and model selection in dynamical
systems. J. R. Soc. Interface 2009;6:187–202 (the Royal Society).
22] Sisson SA, Fan Y, Tanaka MM.  Sequential Monte Carlo without likelihoods. Proc
Natl Acad Sci USA 2007;104:1760–5.
23] Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of
model complexity and ﬁt. J R Stat Soc: Ser B (Stat Methodol) 2002;64:583–639.
24] Ferguson NM,  Donnelly CA, Anderson RM.  Transmission dynamics and epi-
demiology of dengue: insights from age-stratiﬁed sero-prevalence surveys.
Philos Trans R Soc London, Ser B: Biol Sci 1999;354:757–68.
25] Imai N, Dorigatti I, Cauchemez S, Ferguson NM.  Estimating dengue transmission
intensity from sero-prevalence surveys in multiple countries. PLoS Negl Trop
Dis  2015;9:e0003719.
26] Shepard DS, Undurraga EA, Betancourt-Cravioto M,  Guzmán MG,  Halstead SB,
Harris E, et al. Approaches to reﬁning estimates of global burden and economics
of  dengue. PLoS Negl Trop Dis 2014;8:e3306.
27] Rodriguez-Barraquer I, Buathong R, Iamsirithaworn S, Nisalak A, Lessler
J,  Jarman RG, et al. Revisiting Rayong: shifting seroproﬁles of dengue in
Thailand and their implications for transmission and control. Am J Epidemiol
2014;179:353–60.
28] Mizumoto K, Ejima K, Yamamoto T, Nishiura H. On the risk of severe dengue
during secondary infection: a systematic review coupled with mathematical
modeling. J Vector Borne Dis 2014;51:153–64.
29] Reich NG, Shrestha S, King AA, Rohani P, Lessler J, Kalayanarooj S, et al. Inter-
actions between serotypes of dengue highlight epidemiological impact of
cross-immunity. J R Soc Interface 2013;10:20130414.
30] Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, et al. A
shorter time interval between ﬁrst and second dengue infections is associated
with protection from clinical illness in a school-based cohort in Thailand. J
Infect Dis 2014;209:360–8.
31] Sabin AB. Research on dengue during World War  II. Am J Trop Med  Hyg
1952;1:30–50.
32] Thai KT, Nishiura H, Hoang PL, Tran NTT, Phan GT, Le HQ,  et al. Age-speciﬁcity
of clinical dengue during primary and secondary infections. PLoS Negl Trop Dis
2011;5:e1180.
33] Egger JR, Coleman PG. Age and clinical dengue illness. Emergy Infect Dis
2007;13:924–5.
34] Rodriguez-Barraquer I, Mier-y-Teran-Romero L, Schwartz IB, Burke DS, Cum-
mings DA. Potential opportunities and perils of imperfect dengue vaccines.
Vaccine 2014;32:514–20.
35] Grange L, Simon-Loriere E, Sakuntabhai A, Gresh L, Paul R, Harris E. Epidemio-
logical risk factors associated with high global frequency of inapparent dengue
virus infections. Front Immunol 2014;5:280.
36] Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis
2011;52:911–6.
37] De Angelis D, Presanis AM,  Birrell PJ, Tomba GS, House T. Key challenges in infec-
tious disease modelling using data from multiple sources. Epidemics 2015;10.
38] Andrieu C, Doucet A, Holenstein R. Particle markov chain monte carlo methods.
J  R Stat Soc: Ser B: Stat Methodol 2010;72:269–342.
 
–34 (2016) 641 64257 642539] Brooks-Pollock E, Roberts GO, Keeling MJ.  A dynamic model of bovine tubercu-
losis spread and control in Great Britain. Nature 2014;511:228–31.
40] Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitaya-
sunondh T, Dietze R, et al. Efﬁcacy and long-term safety of a dengue vaccine in
regions of endemic disease. N Engl J Med  2015.
